We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Thalidomide as treatment of refractory thoracic Rosai‐Dorfman disease.
- Authors
Hoyo‐Muñoz, Angela; Collado‐Borrell, Roberto; Escudero‐Vilaplana, Vicente; Bastos‐Oreiro, Mariana; Herranz‐Alonso, Ana; Sanjurjo‐Sáez, María
- Abstract
What is Known and Objective: Rosai‐Dorfman disease (RDD) is an infrequent entity of unknown aetiology. Currently, there is no clear consensus on the treatment, and nothing has shown definitive safety and efficacy. We describe the case of a woman diagnosed with pulmonary RDD, who responded to thalidomide treatment after failure of four previous lines of systemic chemotherapy. Case Description: We present the case of a 74‐year‐old woman diagnosed with pulmonary RDD and autoimmune complications. We decided to use thalidomide as a rescue treatment after the failure of corticosteroids and several chemotherapies. Our patient achieved remission of the disease and remained stable for years. What is New and Conclusion: To the authors' knowledge, this is the first reported case in which thalidomide treatment induced remission in refractory pulmonary RDD. Thalidomide showed a rapid onset of action, with lasting responses, which could make it an exciting option for treating this life‐threatening.
- Subjects
THALIDOMIDE; NON-langerhans-cell histiocytosis; LYMPHATIC diseases
- Publication
Journal of Clinical Pharmacy & Therapeutics, 2022, Vol 47, Issue 4, p548
- ISSN
0269-4727
- Publication type
Article
- DOI
10.1111/jcpt.13513